Cardiovascular Involvement in mtDNA Disease: Diagnosis, Management, and Therapeutic Options.
Hypertrophic cardiomyopathy
MELAS syndrome
Mitochondrial diseases
mtDNA
Journal
Heart failure clinics
ISSN: 1551-7136
Titre abrégé: Heart Fail Clin
Pays: United States
ID NLM: 101231934
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
entrez:
15
11
2021
pubmed:
16
11
2021
medline:
26
11
2021
Statut:
ppublish
Résumé
Mitochondrial diseases (MD) include an heterogenous group of systemic disorders caused by sporadic or inherited mutations in nuclear or mitochondrial DNA (mtDNA), causing impairment of oxidative phosphorylation system. Hypertrophic cardiomyopathy is the dominant pattern of cardiomyopathy in all forms of mtDNA disease, being observed in almost 40% of the patients. Dilated cardiomyopathy, left ventricular noncompaction, and conduction system disturbances have been also reported. In this article, the authors discuss the current clinical knowledge on MD, focusing on diagnosis and management of mitochondrial diseases caused by mtDNA mutations.
Identifiants
pubmed: 34776083
pii: S1551-7136(21)00072-6
doi: 10.1016/j.hfc.2021.07.003
pii:
doi:
Substances chimiques
DNA, Mitochondrial
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
51-60Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.